内分类大麻素系统对帕金森病的潜在神经保护作用
María Fernanda Urmeneta-Ortíz1,2, Aldo Rafael Tejeda-Martínez2, Orfil González-Reynoso1
1Chemical Engineering Department, University Center for Exact and Engineering Sciences University of Guadalajara, Blvd. M. García Barragán # 1451, Guadalajara C.P. 44430, Jalisco, Mexico.
Parkinson's disease
|August 6, 2024
概括
内分泌大麻素系统 (ECS) 显示出治疗帕金森病 (PD) 的前景. 向ECS可能为多巴胺能神经元提供神经保护,可能改善PD患者的运动功能.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 帕金森病 (PD) 涉及多巴胺神经元的损失,导致运动缺陷.
- 目前用于PD的治疗方法无法阻止疾病的进展.
- 内分泌大麻素系统 (ECS) 参与了PD的发病和运动症状.
研究的目的:
- 审查当前关于在PD中ECS变化的证据.
- 探索EPS在PD中的神经保护潜力.
- 在ECS中确定PD治疗的潜在药理标.
主要方法:
- 关于临床前和临床研究的综合文献综述.
- 对ECS组件及其在基底腺中的作用的研究分析.
- 对ECS介导的神经保护的证据的评估.
主要成果:
- 在PD中,ECS发生变化,与多巴胺能耗竭相关.
- 欧洲神经系统表现出神经保护机制,包括抗炎,抗氧化和抗质作用.
- 有证据表明,ECS可以保护多巴胺类神经元.
结论:
- 内分泌大麻素系统是帕金森病的一个有前途的治疗点.
- 准ECS可能提供新的策略来保护多巴胺基神经元和管理PD症状.
- 对基于ECS的疗法进行进一步的研究对于PD治疗是有必要的.
相关概念视频
Parkinson's Disease: Treatment
241
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
241
Parkinson's Disease: Overview
508
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
508
Neural Regulation
39.2K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.2K
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
172
CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its...
172
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
207
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
207
Excitatory and Inhibitory Effects of Neurotransmitters
9.9K
When an action potential reaches the presynaptic axon terminal, it releases neurotransmitters from the neuron into the synaptic cleft at a chemical synapse. The released neurotransmitter can be excitatory or inhibitory. The critical criteria commonly used to determine whether a molecule is a neurotransmitter at a chemical synapse are the molecule's presence in the presynaptic neuron. Second, its release is in response to strong presynaptic depolarization. And lastly, the presence of...
9.9K


